by HealthDay Reporter | Mar 1, 2024
Greater mean change from baseline seen in total score on the Scale for the Assessment and Rating of Ataxia with NALL versus placebo. Treatment with N-acetyl-L-leucine (NALL) for 12 weeks yields better neurological status than placebo among patients with...
by HealthDay Reporter | Feb 28, 2024
Approval allows for twice daily oral treatment for 12 weeks in people aged 11 years and older. The U.S. Food and Drug Administration has approved Eohilia (budesonide oral suspension) as the first and only oral treatment for eosinophilic esophagitis...
by HealthDay Reporter | Feb 27, 2024
Triplet therapy of belantamab mafodotin, bortezomib, dexamethasone beneficial for relapsing or refractory multiple myeloma. For patients with relapsed or refractory multiple myeloma (RRMM), triplet therapy of belantamab mafodotin (belamaf) plus...
by HealthDay Reporter | Feb 22, 2024
Approval allows Onivyde (plus oxaliplatin, fluorouracil, and leucovorin) as first-line therapy. The U.S. Food and Drug Administration has approved Onivyde (irinotecan liposome injection) plus oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX) as a...
by HealthDay Reporter | Feb 20, 2024
Twenty-five reports of rare blood cancers in patients who had received CAR T-cell therapy prompted agency’s warning. Citing recent indications that CAR T-cell therapy may cause rare secondary cancers, the U.S. Food and Drug Administration has told...
